No. of Recommendations: 4
Today’s PR
https://www.esperion.com/news-releases/news-releas...Investor preso and a couple Nov science conf events listed here:
https://www.esperion.com/investor-relations/eventsI don’t have the transcript yet, but only thing new of note was around Canada market and expecting a partnership soon. This is potentially important as there may be upfront funds tied to that partnership, and those funds could be used to offset the Nov 2025 Notes that will come due. Some online state once Notes get within a year of their due date, they become liabilities or something like that, on balance sheet…so in your interest to address this month.
The other not really new news but good to hear news was that Japan partner Otsuka is on track to file by EOY, which triggers a milestone payment (I think $25m but not positive).
Still on track is that European partner DSE takes over pill manufacturing in 2025 and apparently on schedule and that reduces costs, improving profitability moving forward.
Right now their pace, with my proj Q4 is about a $120m US sales number for 2024. Again - despite their small cap, I have to remind myself that this is not a no-revenue SPAC or anything. They do over $100m/year in revenue. Their product is real and insurance companies formulary and UM updates show that the product is real, and the sales growth and Rx growth is real.
50% is pretty awesome normally, but the y/y compare feels a bit off bc they were flat for a couple Q’s in 2023 so the compare this Q and in Q4 is a bit easy y/y.
So the time to ramp is now. Definitely not time to slow the Qtrly growth.
Any partnership news can be notable, so let’s see if it happens in next few weeks or not.
Dreamer
